Pharmacyclics, Inc.
PCYCDrugs in Pipeline
22
Phase 3 Programs
9
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
Prednisone (or equivalent)
Lymphoma
Ibrutinib Oral Capsule
Follicular Lymphoma
Motexafin Gadolinium
Brain Neoplasms
MGd
Metastatic Cancer
Next-line ibrutinib
Chronic Lymphocytic Leukemia
Ibrutinib
Diffuse Large B Cell Lymphoma Relapsed
ofatumumab
B-cell Chronic Lymphocytic Leukemia
PCI-32765 (Ibrutinib)
Lymphoma
Chlorambucil
Chronic Lymphocytic Leukemia
GCSF
Sarcoma
Fludarabine
Chronic Lymphocytic Leukemia
HD- Methotrexate (MTX)
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)
GA101
Chronic Lymphocytic Leukemia
Ibrutinib 560 mg
Breast Neoplasms
Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
B-cell Chronic Lymphocytic Leukemia
PCI-24781
Lymphoma
MEDI4736
Diffuse Large B-Cell Lymphoma
Blinatumomab
Adult B Acute Lymphoblastic Leukemia
Motexafin Gadolinium Injection
Multiple Myeloma
PCI-27483
Pancreatic Cancer
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Chronic Lymphocytic Leukemia
PCI-32765
B-cell Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Prednisone (or equivalent) | Phase 3 | Lymphoma | - | - |
Ibrutinib Oral Capsule | Phase 3 | Follicular Lymphoma | - | - |
Motexafin Gadolinium | Phase 3 | Brain Neoplasms | - | - |
MGd | Phase 3 | Metastatic Cancer | - | - |
Next-line ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Ibrutinib | Phase 3 | Diffuse Large B Cell Lymphoma Relapsed | - | - |
ofatumumab | Phase 3 | B-cell Chronic Lymphocytic Leukemia | - | - |
PCI-32765 (Ibrutinib) | Phase 3 | Lymphoma | - | - |
Chlorambucil | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
GCSF | Phase 2 | Sarcoma | - | - |
Fludarabine | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
HD- Methotrexate (MTX) | Phase 2 | Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | - | - |
GA101 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Ibrutinib 560 mg | Phase 2 | Breast Neoplasms | - | - |
Cirmtuzumab (2-16 kg/mg) plus Ibrutinib | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
PCI-24781 | Phase 2 | Lymphoma | - | - |
MEDI4736 | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Blinatumomab | Phase 2 | Adult B Acute Lymphoblastic Leukemia | - | - |
Motexafin Gadolinium Injection | Phase 2 | Multiple Myeloma | - | - |
PCI-27483 | Phase 2 | Pancreatic Cancer | - | - |
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
PCI-32765 | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pharmacyclics, Inc.'s drug pipeline?→
CatalystAlert tracks 22 drug candidates in Pharmacyclics, Inc.'s (PCYC) pipeline across Phase 3, Phase 2. Its lead program is Prednisone (or equivalent) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharmacyclics, Inc.'s next FDA catalyst?→
Pharmacyclics, Inc.'s (PCYC) next tracked catalyst is a Phase 2 expected September 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCYC biotech catalysts?→
Add PCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharmacyclics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.